(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/247708 A1

(51) International Patent Classification:
*A61K 47/68* (2017.01) *A61P 35/00* (2006.01)
*A61K 47/00* (2006.01)

(21) International Application Number:
PCT/CN2022/093632

(22) International Filing Date:
18 May 2022 (18.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202110565350.2 24 May 2021 (24.05.2021) CN

(71) Applicant: **REMEGEN CO., LTD.** [CN/CN]; No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade Zone, Yantai, Shandong 264006 (CN).

(72) Inventors: **FANG, Jianmin**; 58 Middle Beijing Road Yantai, Economic & Technological, Development Area, Yantai, Shandong 264006 (CN). **SU, Xiaohong**; 58 Middle Beijing Road Yantai, Economic & Technological, Development Area, Yantai, Shandong 264006 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3 FL, Building 2, Yard 3, FengXiuZhongLu Road, Haidian District, Beijing 100094 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *of inventorship (Rule 4.17(iv))*
— *as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))*

**Published:**
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2022/247708 A1

(54) Title: USE OF HER2-TARGETING ANTIBODY-DRUG CONJUGATE IN TREATMENT OF HER2-LOW EXPRESSING BREAST CANCER

(57) Abstract: Provided is a method for treating a patient with Human Epidermal Growth Factor Receptor 2 (HER2) -low expressing breast cancer.